2018 Guidelines for the Management of Dyslipidemia in Korea

키워드

참고문헌 (210)

1. "Global Health Observatory (GHO) data" (2019)[URL]
2. "Preventing chronic diseases: a vital investment" (2019)[URL]
3. 홍재석, "Long-Term Trend in the Incidence of Acute Myocardial Infarction in Korea: 1997-2007", Korean Circulation Journal, 39(11), pp.467~476 (2009), 대한심장학회
4. 김록범, "Trends in the Incidence of Hospitalized Acute Myocardial Infarction and Stroke in Korea, 2006-2010", Journal of Korean Medical Science, 28(1), pp.16~24 (2013), 대한의학회
5. Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
6. Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
7. Jellinger PS, "American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease", Endocr Pract, 23(Suppl 2), pp.1~87 (2017)
8. Dicembrini I, "Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials", J Endocrinol Invest (2019)
9. 2012 Private Subsidized Project on the Computation of the Incidence of Myocardial Infarction, "Yonsei University", Yonsei University, ~ (2013)
10. The World Health Organization MONICA Project, "Ecological analysis of the association between mortality and major risk factors of cardiovascular disease", Int J Epidemiol, 23, pp.505~516 (1994)
11. 2017 Chronic Diseases and Issues: Chronic Disease Factbook, "Korea Centers for Disease Control and Prevention", Korea Centers for Disease Control and Prevention, ~ (2017)
12. 김현창, "Noncommunicable Diseases: Current Status of Major Modifiable Risk Factors in Korea", 예방의학회지, 46(4), pp.165~172 (2013), 대한예방의학회
13. Jee SH, "A coronary heart disease prediction model: the Korean Heart Study", BMJ Open, 4, pp.e005025~ (2014)
14. Korean Society for Preventive Medicine, "Clinical Preventive Medicine Based on Scientific Evidence", pp.183~221 (2011), Gyechuk Munhwasa
15. Wilson PW, "Prediction of coronary heart disease using risk factor categories", Circulation, 97, pp.1837~1847 (1998)
16. D'Agostino RB Sr, "Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation", JAMA, 286, pp.180~187 (2001)
17. Eichler K, "Prediction of first coronary events with the Framingham score: a systematic review", Am Heart J, 153, pp.722~731 (2007)
18. Jee SH, "Stroke risk prediction model: a risk profile from the Korean study", Atherosclerosis, 197, pp.318~325 (2008)
19. Park GM, "Model for assessing cardiovascular risk in a Korean population", Circ Cardiovasc Qual Outcomes, 7, pp.944~951 (2014)
20. 박지혜, "Effects of Age, Sex, and Menopausal Status on Blood Cholesterol Profile in the Korean Population", Korean Circulation Journal, 45(2), pp.141~148 (2015), 대한심장학회
21. 2016 National Health Statistics I, 7th National Health and Nutrition Examination Survey: First Year (2016), "Ministry of Health and Welfare", Korea Centers for Disease Control and Prevention, ~ (2017)
22. 김현창, "한국인 이상지질혈증의 역학", 대한의사협회지, 59(5), pp.352~357 (2016), 대한의사협회[DOI]
23. "Dyslipidemia fact sheets in Korea, 2018" (2018)[URL]
24. Stone NJ, "ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
25. Vaucher J, "Population and economic impact of the 2013 ACC", AHA guidelines compared with European guidelines to prevent cardiovascular disease, 2014, pp.35, 958~959
26. LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", N Engl J Med, 352, pp.1425~1435 (2005)
27. Cholesterol Treatment Trialists' (CTT) Collaboration, "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
28. Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2018 executive summary", Endocr Pract, 24, pp.91~120 (2018)
29. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
30. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
31. Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
32. Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
33. NIPPON DATA80 Research Group, "Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population", Circ J, 70, pp.1249~1255 (2006)
34. de Lemos JA, "Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial", JAMA, 292, pp.1307~1316 (2004)
35. Lee KH, "Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol", J Am Coll Cardiol, 58, pp.1664~1671 (2011)
36. Heart Protection Study Collaborative Group, "MRC", BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, 2002, pp.360, 7~22
37. Grundy SM, "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines", J Am Coll Cardiol, 44, pp.720~732 (2004)
38. Ferguson GG, "The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients", Stroke, 30, pp.1751~1758 (1999)
39. "Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)", Lancet, 351, pp.1379~1387 (1998)
40. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
41. Furberg CD, "Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group", Circulation, 90, pp.1679~1687 (1994)
42. Teramoto T, "Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan: 2012 version", J Atheroscler Thromb, 20, pp.517~523 (2013)
43. Toskes PP, "Hyperlipidemic pancreatitis", Gastroenterol Clin North Am, 19, pp.783~791 (1990)
44. Studer M, "Effect of different antilipidemic agents and diets on mortality: a systematic review", Arch Intern Med, 165, pp.725~730 (2005)
45. Jun M, "Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis", Lancet, 375, pp.1875~1884 (2010)
46. ACCORD Study Group, "Effects of combination lipid therapy in type 2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
47. Poobalan A, "Effects of weight loss in overweight", obese individuals and long-term lipid outcomes: a systematic review, 2004, pp.5, 43~50
48. Korean Society for the Study of Obesity, "Guideline for the Management of Obesity", 26~30 (2018)
49. Rees K, "Dietary advice for reducing cardiovascular risk", Cochrane Database Syst Rev, 12, pp.CD002128~ (2013)
50. 2015 National Health Statistics: 6th National Health and Nutrition Examination Survey: Third Year (2015), "Ministry of Health and Welfare", Korea Centers for Disease Control and Prevention, ~ (2015)
51. Ministry of Health and Welfare, "Dietary Reference Intake for Koreans 2015", Korean Nutrition Society, ~ (2015)
52. Mensink RP, "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials", Am J Clin Nutr, 77, pp.1146~1155 (2003)
53. Eckel RH, "2013 AHA", ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
54. Harris WS, "n-3 fatty acids and serum lipoproteins: human studies", Am J Clin Nutr, 65(5 Suppl), pp.1645S~1654S (1997)
55. Brown L, "Cholesterol-lowering effects of dietary fiber: a meta-analysis", Am J Clin Nutr, 69, pp.30~42 (1999)
56. Anderson JW, "Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence", J Am Coll Nutr, 23, pp.5~17 (2004)
57. Chrysohoou C, "Effects of chronic alcohol consumption on lipid levels, inflammatory and haemostatic factors in the general population: the ‘ATTICA’ Study", Eur J Cardiovasc Prev Rehabil, 10, pp.355~361 (2003)
58. Fletcher GF, "Exercise standards for testing and training: a scientific statement from the American Heart Association", Circulation, 128, pp.873~934 (2013)
59. Taylor RS, "Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials", Am J Med, 116, pp.682~692 (2004)
60. Kraus WE, "Effects of the amount and intensity of exercise on plasma lipoproteins", N Engl J Med, 347, pp.1483~1492 (2002)
61. Haskell WL, "Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association", Circulation, 116, pp.1081~1093 (2007)
62. Kavazis AN, "Exercise preconditioning of the myocardium", Sports Med, 39, pp.923~935 (2009)
63. 2018 Physical Activity Guidelines Advisory Committee Scientific Report, "2018 Physical Activity Guidelines Advisory Committee", U.S. Department of Health and Human Services, ~ (2018)
64. Kelley GA, "Impact of progressive resistance training on lipids and lipoproteins in adults : a meta-analysis of randomized controlled trials", Prev Med, 48, pp.9~19 (2009)
65. Kelley GA, "Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals", Prev Med, 49, pp.473~475 (2009)
66. Perk J, "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)", Eur Heart J, 33, pp.1635~1701 (2012)
67. Moriguchi EH, "Effects of smoking on HDL subfractions in myocardial infarction patients: effects on lecithin-cholesterol acyltransferase and hepatic lipase", Clin Chim Acta, 195, pp.139~143 (1991)
68. Hellerstein MK, "Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers", J Clin Invest, 93, pp.265~272 (1994)
69. McCall MR, "Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk", Arterioscler Thromb, 14, pp.248~253 (1994)
70. Craig WY, "Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data", BMJ, 298, pp.784~788 (1989)
71. Stubbe I, "High-density lipoprotein concentrations increase after stopping smoking", Br Med J (Clin Res Ed), 284, pp.1511~1513 (1982)
72. Gepner AD, "Effects of smoking and smoking cessation on lipids and lipoproteins : outcomes from a randomized clinical trial", Am Heart J, 161, pp.145~151 (2011)
73. Prescott E, "Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality: a 22 year follow up of 12 149 men and women in the Copenhagen City Heart Study", J Epidemiol Community Health, 56, pp.702~706 (2002)
74. "NICE Public Health Guidance 10. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities" (2019)[URL]
75. Law MR, "Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence", BMJ, 315, pp.973~980 (1997)
76. Mohiuddin SM, "Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease", Chest, 131, pp.446~452 (2007)
77. Anthonisen NR, "The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial", Ann Intern Med, 142, pp.233~239 (2005)
78. Reiner Z, "Combined therapy in the treatment of dyslipidemia", Fundam Clin Pharmacol, 24, pp.19~28 (2010)
79. Khang AR, "Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes", J Clin Lipidol, 10, pp.528~537 (2016)
80. "ODYSSEY Outcomes: results suggest use of PCSK9 inhibitor reduces CV events, LDL-C in ACS patients" (2018)[URL]
81. Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial", Lancet, 366, pp.1849~1861 (2005)
82. Balk EM, "Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review", Atherosclerosis, 189, pp.19~30 (2006)
83. Yokoyama M, "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis", Lancet, 369, pp.1090~1098 (2007)
84. Davidson MH, "Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g", d to simvastatin 40 mg, Clin Ther, pp.2007, 29[DOI]
85. Vaughan CJ, "Update on statins : 2003", Circulation, 110, pp.886~892 (2004)
86. Cholesterol Treatment Trialists' (CTT) Collaborators, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials", Lancet, 380, pp.581~590 (2012)
87. Tobert JA, "Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors", Nat Rev Drug Discov, 2, pp.517~526 (2003)
88. Gotto AM Jr, "Drugs for the Heart", pp.398~435 (2013), Elsevier Saunders
89. Jones PH, "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)", Am J Cardiol, 92, pp.152~160 (2003)
90. Nicholls SJ, "Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)", Am J Cardiol, 105, pp.69~76 (2010)
91. "Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin: final report update 5" (2009)[URL]
92. Lee HJ, "Effects of lovastatin(Mevacor®)on lowering plasma lipids in patients with hyperlipidemia", Korean Circ J, 21, pp.781~785 (1991)
93. Yoo WS, "Effect of lovastatin(Mevacor®)on serum lipids of patients with primary hyperlipidemia", Korean Circ J, 19, pp.489~496 (1989)
94. Bae JH, "Hypolipidemic effects and safety of lovastatin in patients with primary hypercholesterolemia", Korean Circ J, 21, pp.129~136 (1991)
95. Koh KK, "Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients", Int J Cardiol, 166, pp.509~515 (2013)
96. Koh KK, "Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia", Diabetes, 62, pp.3547~3552 (2013)
97. Kim SH, "Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability", Eur J Clin Nutr, 65, pp.110~116 (2011)
98. Kim SH, "Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia : a randomized, double-blind, multicenter phase III trial", Clin Ther, 35, pp.1350~1360 (2013)
99. Park S, "A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia", Clin Ther, 27, pp.1074~1082 (2005)
100. Atorvastatin Study Group in Korea, "Flexible Initial Dosing of Atorvastatin Based Upon Initial Low-Density Lipoprotein Cholesterol Levels in Type 2 Diabetic Patients", The Korean Journal of Internal Medicine, 23(1), pp.22~29 (2008), 대한내과학회
101. Koh KK, "Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients", J Am Coll Cardiol, 55, pp.1209~1216 (2010)
102. 박종선, "Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia", The Korean Journal of Internal Medicine, 25(1), pp.27~35 (2010), 대한내과학회
103. Her AY, "Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin", ezetimibe 5 mg, J Cardiovasc Pharmacol Ther, pp.2010, 15[DOI]
104. Kim SH, "Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg", d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial, 2010, pp.32, 1896~1905
105. Kim SH, "Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial", Clin Ther, 35, pp.77~86 (2013)
106. Lee CW, "Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial)", Am J Cardiol, 109, pp.1700~1704 (2012)
107. Lee JH, "Effects of ezetimibe", simvastatin 10, apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial, pp.Am J Cardiovasc Drugs, 2013[DOI]
108. Lee SH, "The effects of statin monotherapy and low-dose statin", ezetimibe on lipoprotein-associated phospholipase A₂, 2011, pp.34, 108~112
109. Hong YJ, "Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis", Circ J, 75, pp.398~406 (2011)
110. Lee SH, "Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia", Atherosclerosis, 221, pp.169~175 (2012)
111. Lee SH, "Comparison of the efficacy and tolerability of pitavastatin and atorvastatin : an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia", Clin Ther, 29, pp.2365~2373 (2007)
112. Weng TC, "A systematic review and meta-analysis on the therapeutic equivalence of statins", J Clin Pharm Ther, 35, pp.139~151 (2010)
113. Mukhtar RY, "Pitavastatin", Int J Clin Pract, 59, pp.239~252 (2005)
114. Baigent C, "Efficacy and safety of cholesterollowering treatment : prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)
115. Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
116. Shepherd J, "PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial", Lancet, 360, pp.1623~1630 (2002)
117. Taylor F, "Statins for the primary prevention of cardiovascular disease", Cochrane Database Syst Rev, 1, pp.CD004816~ (2011)
118. Mills EJ, "Primary prevention of cardiovascular mortality and events with statin treatments : a network meta-analysis involving more than 65, 000 patients", J Am Coll Cardiol, 52, pp.1769~1781 (2008)
119. Nakamura H, "Primary prevention of cardiovascular disease with pravastatin in Japan(MEGA Study) : a prospective randomised controlled trial", Lancet, 368, pp.1155~1163 (2006)
120. Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
121. Eckel RH, "Approach to the patient who is intolerant of statin therapy", J Clin Endocrinol Metab, 95, pp.2015~2022 (2010)
122. Dale KM, "Impact of statin dosing intensity on transaminase and creatine kinase", Am J Med, 120, pp.706~712 (2007)
123. Berglund L, "Evaluation and treatment of hypertriglyceridemia : an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 97, pp.2969~2989 (2012)
124. Harris WS, "Safety and efficacy of Omacor in severe hypertriglyceridemia", J Cardiovasc Risk, 4, pp.385~391 (1997)
125. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico, "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction : results of the GISSIPrevenzione trial", Lancet, 354, pp.447~455 (1999)
126. Glauber H, "Adverse metabolic effect of omega-3 fatty acids in noninsulin-dependent diabetes mellitus", Ann Intern Med, 108, pp.663~668 (1988)
127. Annuzzi G, "A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients", Atherosclerosis, 87, pp.65~73 (1991)
128. Kaushik M, "Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus", Am J Clin Nutr, 90, pp.613~620 (2009)
129. Wu JH, "Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis", Br J Nutr, 107(Suppl 2), pp.S214~S227 (2012)
130. Pedersen HS, "N-3 fatty acids as a risk factor for haemorrhagic stroke", Lancet, 353, pp.812~813 (1999)
131. Gajos G, "Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot)", Arterioscler Thromb Vasc Biol, 31, pp.1696~1702 (2011)
132. Wu D, "n-3 polyunsaturated fatty acids and immune function", Proc Nutr Soc, 57, pp.503~509 (1998)
133. AIM-HIGH Investigators, "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", N Engl J Med, 365, pp.2255~2267 (2011)
134. Rossebø AB, "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis", N Engl J Med, 359, pp.1343~1356 (2008)
135. Baigent C, "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial", Lancet, 377, pp.2181~2192 (2011)
136. Cannon CP, "Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe", simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, 2008, pp.156, 826~832
137. Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)
138. Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
139. Athyros VG, "Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia", J Cardiovasc Risk, 9, pp.33~39 (2002)
140. Farnier M, "Fixed-dose combination fenofibrate", pravastatin 160, Clin Ther, pp.2011, 33[DOI]
141. Zhao XQ, "Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome : a combined analysis of the Familial Atherosclerosis Treatment Study(FATS), the HDL-Atherosclerosis Treatment Study(HATS), and the Armed Forces Regression Study(AFREGS)", Am J Cardiol, 104, pp.1457~1464 (2009)
142. Galan P, "Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial", BMJ, 341, pp.c6273~ (2010)
143. HPS2-THRIVE Collaborative Group, "Effects of extended-release niacin with laropiprant in high-risk patients", N Engl J Med, 371, pp.203~212 (2014)
144. Amarenco P, "Statins in stroke prevention and carotid atherosclerosis : systematic review and up-to-date meta-analysis", Stroke, 35, pp.2902~2909 (2004)
145. Hosomi N, "The Japan Statin Treatment Against Recurrent Stroke(J-STARS) : a multicenter, randomized, open-label, parallel-group study", EBioMedicine, 2, pp.1071~1078 (2015)
146. Goldstein LB, "Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study", Neurology, 70(24 Pt 2), pp.2364~2370 (2008)
147. Tonelli M, "Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline", Ann Intern Med, 160, pp.182~ (2014)
148. Holdaas H, "Effect of fluvastatin on cardiac outcomes in renal transplant recipients : a multicentre, randomised, placebo-controlled trial", Lancet, 361, pp.2024~2031 (2003)
149. Wanner C, "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis", N Engl J Med, 353, pp.238~248 (2005)
150. Fellström BC, "Rosuvastatin and cardiovascular events in patients undergoing hemodialysis", N Engl J Med, 360, pp.1395~1407 (2009)
151. European Association for Cardiovascular Prevention & Rehabilitation, "ESC", EAS guidelines for the management of dyslipidaemias : the task force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS), 2011, pp.32, 1769~1818
152. Zhao YY, "New fibrate use and acute renal outcomes in elderly adults : a population-based study", Ann Intern Med, 156, pp.560~569 (2012)
153. Harper CR, "Managing dyslipidemia in chronic kidney disease", J Am Coll Cardiol, 51, pp.2375~2384 (2008)
154. Kidney Disease Outcomes Quality Initiative (K, "DOQI) Group", K, Am J Kidney Dis, pp.2003, 41(4 Suppl 3)[DOI]
155. Davidson MH, "Safety considerations with fibrate therapy", Am J Cardiol, 99(6A), pp.3C~18C (2007)
156. Mottillo S, "The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis", J Am Coll Cardiol, 56, pp.1113~1132 (2010)
157. Haffner SM, "Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction", N Engl J Med, 339, pp.229~234 (1998)
158. Boekholdt SM, "Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis", JAMA, 307, pp.1302~1309 (2012)
159. Ilanne-Parikka P, "Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study", Diabetes Care, 31, pp.805~807 (2008)
160. Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS) : multicentre randomised placebo-controlled trial", Lancet, 364, pp.685~696 (2004)
161. Shepherd J, "Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study", Diabetes Care, 29, pp.1220~1226 (2006)
162. 이승환, "Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study", Diabetes and Metabolism Journal, 38(1), pp.64~73 (2014), 대한당뇨병학회[DOI]
163. Sacks FM, "Combination lipid therapy in type 2 diabetes", N Engl J Med, 363, pp.692~694 (2010)
164. Moriarty PM, "Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients : design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial", J Clin Lipidol, 8, pp.554~561 (2014)
165. Zhang XL, "Safety and efficacy of anti-PCSK9 antibodies : a meta-analysis of 25 randomized, controlled trials", BMC Med, 13, pp.123~ (2015)
166. "Statistical report of population and housing census in 2017" (1996)[URL]
167. Glynn RJ, "Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial", Ann Intern Med, 152, pp.488~496 (2010)
168. Neil HA, "Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)", Diabetes Care, 29, pp.2378~2384 (2006)
169. Wenger NK, "Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease", Ann Intern Med, 147, pp.1~9 (2007)
170. Lewis SJ, "Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial", Ann Intern Med, 129, pp.681~689 (1998)
171. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, "Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report", Pediatrics, 128(Suppl 5), pp.S213~S256 (2011)
172. Yang S, "Serum lipid concentrations, prevalence of dyslipidemia, and percentage eligible for pharmacological treatment of Korean children and adolescents; data from the Korea National Health and Nutrition Examination Survey IV(2007-2009)", PLoS One, 7, pp.e49253~ (2012)
173. Srinivasan SR, "Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks : the Bogalusa Heart Study", Pediatrics, 118, pp.201~206 (2006)
174. Cui Y, "Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality", Arch Intern Med, 161, pp.1413~1419 (2001)
175. Frontini MG, "Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults(The Bogalusa Heart Study)", Am J Cardiol, 100, pp.64~68 (2007)
176. Daniels SR, "Pediatric guidelines for dyslipidemia", J Clin Lipidol, 9(5 Suppl), pp.S5~S10 (2015)
177. McCrindle BW, "Drug therapy of high-risk lipid abnormalities in children and adolescents : a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing", Circulation, 115, pp.1948~1967 (2007)
178. National Cholesterol Education Program (NCEP), "highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents", Pediatrics, 89, pp.495~501 (1992)
179. Manlhiot C, "Spectrum and management of hypertriglyceridemia among children in clinical practice", Pediatrics, 123, pp.458~465 (2009)
180. Austin MA, "Genetic causes of monogenic heterozygous familial hypercholesterolemia : a HuGE prevalence review", Am J Epidemiol, 160, pp.407~420 (2004)
181. Marks D, "A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia", Atherosclerosis, 168, pp.1~14 (2003)
182. Hovingh GK, "Diagnosis and treatment of familial hypercholesterolaemia", Eur Heart J, 34, pp.962~971 (2013)
183. Gidding SS, "The agenda for familial hypercholesterolemia : a scientific statement from the American Heart Association", Circulation, 132, pp.2167~2192 (2015)
184. Landmesser U, "2017 Update of ESC", EAS task force on practical clinical guidance for proprotein convertase subtilisin, Eur Heart J, pp.2018, 39[DOI]
185. Butte NF, "Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus", Am J Clin Nutr, 71(5 Suppl), pp.1256S~1261S (2000)
186. Herrera E, "Role of lipoprotein lipase activity on lipoprotein metabolism and the fate of circulating triglycerides in pregnancy", Am J Obstet Gynecol, 158(6 Pt 2), pp.1575~1583 (1988)
187. Jovanovic L, "The Diabetes in Early Pregnancy Study: beta-hydroxybutyrate levels in type 1 diabetic pregnancy compared with normal pregnancy. NICHD-Diabetes in Early Pregnancy Study Group (DIEP). National Institute of Child Health and Development", Diabetes Care, 21, pp.1978~1984 (1998)
188. Jellinger PS, "American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis", Endocr Pract, 18(Suppl 1), pp.1~78 (2012)
189. Touboul PJ, "Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011", Cerebrovasc Dis, 34, pp.290~296 (2012)
190. French Study of Aortic Plaques in Stroke Group, "Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke", N Engl J Med, 334, pp.1216~1221 (1996)
191. Task Force Members, "2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology", Eur Heart J, 34, pp.2949~3003 (2013)
192. Bedi US, "Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal : medial thickness : a meta-analysis of randomized controlled trials", J Cardiovasc Pharmacol Ther, 15, pp.268~273 (2010)
193. Meschia JF, "Guidelines for the primary prevention of stroke : a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 3754~3832
194. McClelland RL, "Distribution of coronary artery calcium by race, gender, and age : results from the Multi-Ethnic Study of Atherosclerosis(MESA)", Circulation, 113, pp.30~37 (2006)
195. Allison MA, "Patterns and risk factors for systemic calcified atherosclerosis", Arterioscler Thromb Vasc Biol, 24, pp.331~336 (2004)
196. Jensky NE, "Blood pressure and vascular calcification", Hypertension, 55, pp.990~997 (2010)
197. Rennenberg RJ, "Vascular calcifications as a marker of increased cardiovascular risk : a meta-analysis", Vasc Health Risk Manag, 5, pp.185~197 (2009)
198. Park KY, "Association between cerebral arterial calcification and brachial-ankle pulse wave velocity in patients with acute ischemic stroke", Eur Neurol, 61, pp.364~370 (2009)
199. Tsuchiya M, "Stiffness and impaired blood flow in lower-leg arteries are associated with severity of coronary artery calcification among asymptomatic type 2 diabetic patients", Diabetes Care, 27, pp.2409~2415 (2004)
200. Chung PW, "Intracranial internal carotid artery calcification : a representative for cerebral artery calcification and association with white matter hyperintensities", Cerebrovasc Dis, 30, pp.65~71 (2010)
201. Chung PW, "Carotid artery calcification is associated with deep cerebral microbleeds", Eur Neurol, 72, pp.60~63 (2014)
202. Tinana A, "Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments", Am J Cardiol, 89, pp.757~760 (2002)
203. O'Rourke RA, "American College of Cardiology", American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease, 2000, pp.36, 326~340
204. Sangiorgi G, "Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans : a histologic study of 723 coronary artery segments using nondecalcifying methodology", J Am Coll Cardiol, 31, pp.126~133 (1998)
205. Detrano R, "Coronary calcium as a predictor of coronary events in four racial or ethnic groups", N Engl J Med, 358, pp.1336~1345 (2008)
206. American Diabetes Association, "9. Cardiovascular disease and risk management: standards of medical care in diabetes: 2018", Diabetes Care, 41(Suppl 1), pp.S86~S104 (2018)
207. Marwan M, "Clinical characteristics of patients with obstructive coronary lesions in the absence of coronary calcification : an evaluation by coronary CT angiography", Heart, 95, pp.1056~1060 (2009)
208. Goff DC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
209. Conroy RM, "Estimation of ten-year risk of fatal cardiovascular disease in Europe : the SCORE project", Eur Heart J, 24, pp.987~1003 (2003)
210. Hajifathalian K, "A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys", Lancet Diabetes Endocrinol, 3, pp.339~355 (2015)

관련 논문AI추천